Vertaling van "concerned " (Nederlands → Frans) :

narcotics and concerning risk limitation and therapeutic advice and of 22 January 1998 governing certain psychotropic substances and concerning risk limitation and therapeutic advice and of 12 April 1974 containing certain provisions relating to substances with hormonal, antihormonal, anabolic, beta-adrenergic, anti-infectious, antiparasitic and anti-inflammatory action Law of 15 July 1985 on the use in animals of substances with hormonal, anti-hormonal, beta-adrenergic or production stimulating action Law of 13 June 1986 on the removal and transplanting of organs, with regard to cells and tissues Law of 28 August 1991 on the practice of veterinary medicine, regarding the provision of medicines to animal carers Law of 5 July 1994 on blood and blood derivatives of human origin Law of 7 May 2004 on experiments on the human person Royal decree of 31 May 1885 approving new instructions for physicians, pharmacists and druggists Royal decree of 22 September 1966 on the conditions and arrangements for the recognition of laboratories for the analysis and checking of medicines Royal decree of 6 June 1960 on the production, preparation and wholesale distribution and delivery of medicines Royal decree no. 78 of 10 November 1967 on the practice of the healthcare professions regarding the dispensing of medicines to the public and Royal decree of 25 September
narcotics and concerning risk limitation and therapeutic advice and of 22 January 1998 governing certain psychotropic substances and concerning risk limitation and therapeutic advice and of 12 April 1974 containing certain provisions relating to substances with hormonal, antihormonal, anabolic, beta-adrenergic, anti-infectious, antiparasitic and anti-inflammatory action Law of 15 July 1985 on the use in animals of substances with hormonal, anti-hormonal, beta-adrenergic or production stimulating action Law of 13 June 1986 on the removal and transplanting of organs, with regard to cells and tissues Law of 28 August 1991 on the practice of veterinary medicine, regarding the provision of medicines to animal carers Law of 5 July 1994 on blood and blood derivatives of human origin Law of 7 May 2004 on experiments on the human person Royal decree of 31 May 1885 approving new instructions for physicians, pharmacists and druggists Royal decree of 22 September 1966 on the conditions and arrangements for the recognition of laboratories for the analysis and checking of medicines Royal decree of 6 June 1960 on the production, preparation and wholesale distribution and delivery of medicines Royal decree no. 78 of 10 November 1967 on the practice of the healthcare professions regarding the dispensing of medicines to the public and Royal decree of 25 September

This account is concerned with the part played by the CGG in the co-operation concerning the suicidal patient. It also discusses the steps that need to be taken in crisis situations… For the CGG teams who deal with children and teenagers, there is a written account devoted to under-age suicidal patients and those close to them.
Ce protocole s’intéresse au rôle des CGG dans la collaboration autour du patient suicidaire, les démarches à suivre dans des situations de crise… Pour les équipes des CGG qui s’occupent des enfants et des jeunes, un protocole a été créé pour les patients suicidaires mineurs et leurs proches.

The Council urges the authorities competent for public health to make available both this information and these warnings to the target audience of energy drinks. Finally, it requests the legislator to take the necessary measures concerning the labelling of these drinks, especially as far as the recommendations mentioned in this report are concerned.
Enfin, il encourage les autorités de Santé à diffuser, auprès du public cible des boissons énergisantes, les informations reprises ci-avant ainsi que les mises en garde énoncées et sollicite le législateur pour qu’il prenne des dispositions utiles concernant l’étiquetage de ces boissons, notamment quant aux recommandations évoquées dans ce rapport.

Committee is primarily concerned with the ethical and medical aspects, and is the body that has to provide explicit authorisation to allow a clinical trial to start.
Committee is primarily concerned with the ethical and medical aspects, and is the body that has to provide explicit authorisation to allow a clinical trial to start.

een sterke reductie in het aantal te evalueren dossiers waar we Concerned Member State (CMS) zijn in de wederzijdse erkenningsprocedure (MRP) en decentrale procedure (DCP);
La forte réduction du nombre de dossiers à évaluer pour lesquels nous sommes Concerned Member State (CMS) dans la procédure de reconnaissance mutuelle (MRP) et dans la procédure décentralisée (DCP) ;

- wederzijdse erkenningsprocedure en gedecentraliseerde procedure MRP/DCP (PPT, 248 Kb) ; Strategy paper (PDF, 13.4 Kb) for RMS request in view of the Decentralized procedure (DCP) concerning medicinal products for human use (update 04/2013) ; DCP Request Template (DOC, 121 Kb)
- procédure de reconnaissance mutuelle et procédure décentralisée MRP/DCP (PPT, 248 Kb) ; Strategy paper (PDF, 13.4 Kb) for RMS request in view of the Decentralized Procedure (DCP) concenring medicinal products for human use (update 04/2013) ; Template for DCP Request (DOC, 121 Kb)

The FAMHP is concerned with the evaluation of preclinical and quality aspects of a trial.
The FAMHP is concerned with the evaluation of preclinical and quality aspects of a trial.

A text is being prepared within the FAMHP in collaboration with various parties concerned which will enable a realistic approach to be adopted.
A text is being prepared within the FAMHP in collaboration with various parties concerned which will enable a realistic approach to be adopted.

Adviesbrief Réponse aux questions posées par Madame la Ministre L. Onkelinx concernant l’avis CSS 8666 relatif aux acides gras trans (AGT) d’origine industrielle (HGR 8909) (enkel in het Frans beschikbaar)
Réponse aux questions posées par Madame la Ministre L. Onkelinx concernant l’avis CSS 8666 relatif aux acides gras trans (AGT) d’origine industrielle (CSS 8909)

Concerning module 3: 16 revised evaluation reports: 9 complex, 5 pharmaceutical forms and 2 dilution types, with a compilation of the remarks
Concerning module 3: 16 revised evaluation reports: 9 complex, 5 pharmaceutical forms and 2 dilution types, with a compilation of the remarks